77 related articles for article (PubMed ID: 37052226)
1. 1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.
Grob NM; Schibli R; Béhé M; Valverde IE; Mindt TL
ACS Med Chem Lett; 2021 Apr; 12(4):585-592. PubMed ID: 33859799
[TBL] [Abstract][Full Text] [Related]
2. Precision peptide theranostics: developing
Rahimi MN; Corlett A; Van Zuylekom J; Sani MA; Blyth B; Thompson P; Roselt PD; Haskali MB
Theranostics; 2024; 14(5):1815-1828. PubMed ID: 38505611
[TBL] [Abstract][Full Text] [Related]
3. Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability.
Guarrochena X; Kanellopoulos P; Stingeder A; Rečnik LM; Feiner IVJ; Brandt M; Kandioller W; Maina T; Nock BA; Mindt TL
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543286
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution Assessment of a Novel
Pavone AM; Benfante V; Giaccone P; Stefano A; Torrisi F; Russo V; Serafini D; Richiusa S; Pometti M; Scopelliti F; Ippolito M; Giannone AG; Cabibi D; Asti M; Vettorato E; Morselli L; Merone M; Lunardon M; Andrighetto A; Tuttolomondo A; Cammarata FP; Verona M; Marzaro G; Mastrotto F; Parenti R; Russo G; Comelli A
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541733
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-2 receptor targeting by [
Di Santo G; Santo G; Martinovic V; Wolf D; Pircher A; Sviridenko A; Löffler-Ragg J; von Guggenberg E; Virgolini I
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38740575
[No Abstract] [Full Text] [Related]
6. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
[TBL] [Abstract][Full Text] [Related]
7. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
8. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
11. Effect of
Hörmann AA; Klingler M; Rangger C; Mair C; Joosten L; Franssen GM; Laverman P; von Guggenberg E
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986657
[TBL] [Abstract][Full Text] [Related]
12. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis.
Bartz-Kurycki MA; Oluwo OE; Morris-Wiseman LF
Ther Adv Endocrinol Metab; 2021; 12():20420188211049611. PubMed ID: 34659736
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]